Pharmaxis Announces First Results in Bone Marrow Cancer Trial
Release Date: 29/06/2021 12:28pm
First Dose Level in PXS-5505 Myelofibrosis Study Showing Strong Inhibition of Target Enzymes LOX and LOKL2 in Patients
Dosing Commenced in Second Cohort Following Successful Recruitment
Clinical stage drug development company Pharmaxis Ltd (ASX: PXS) today announced results of data analysis from the first of three stages in its phase 1c clinical trial (MF-101) studying a potential new treatment for the bone marrow cancer myelofibrosis. In addition to the good tolerability and consistent pharmacokinetic properties previously announced, the inhibition of two target enzymes, LOX and LOXL2, were assessed with Pharmaxis proprietary assays and found to be highly statistically significant.
Categories: News and Media